Celera Diagnostics, Merck Form Research Collaboration

Oct 20, 2003

NEW YORK, Oct. 20 (GenomeWeb News) - Celera Diagnostics said today that it has formed a research collaboration with Rosetta Inpharmatics, and its parent company Merck, to identify and validate genetic markers that can be used to develop tests and treatments for select cancers.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Breaking News

The Scan

More to Go Around

Congress approved a bill Friday that would increase the US National Institutes of Health's funding by $2 billion for fiscal year 2019.

Call for Ban

UK's Labour Party calls for a ban on non-invasive prenatal testing for determining sex, BBC News reports.

To Worry or Not?

Sarah Lawrence College's Laura Hercher warns in a New York Times op-ed that more people are going to need help figuring out what their consumer genetic testing results mean.

This Week in PLOS

In PLOS this week: intra-tumor heterogeneity patterns, genomic analysis of Thoroughbred horse origins, and more.

Main menu